BPPV, history of gout associated with Ménière's disease

Published Date: 02 Mar 2023

According to a study published online Dec. 26 in the Journal of Clinical Medicine, a history of gout is associated with an increased risk of benign paroxysmal positional vertigo (BPPV) and Ménière's disease.

Read Full News

Latest News

Unraveling the Complexities of Concomitant IBD and Hepatobiliary Disease, With Natalia Nedelkopoulou, MD Natalia Nedelkopoulou, MD

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

Navigating Autoimmune Overlap in Celiac Disease, With Daniel Mallon, MD Daniel Mallon, MD

Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD Bruce Sands, MD

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Latest News

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

News All Time

Young Adults With IBD Face Greater Healthcare Access Challenges, Financial Burdens

Gastroenterology in 2025: Year in Review

Young Women With Ulcerative Colitis Face Higher Corticosteroid Exposure Risk

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD Thomas Wallach, MD

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

According to JAMA, even four minutes a day of exercise can lower the risk of cancer.

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

For treatment, the majority of cancer patients choose complementary therapies.

3.

Food insecurity linked to tumor growth in pediatric neuroblastoma

4.

Getting ahead of head and neck cancer

5.

In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.

1.

The Pivotal Role of Telomerase in Breast Cancer Therapy Resistance and Treatment Strategies

2.

Unleashing Precision Medicine: CRISPR-Cas9 Gene Editing in Hematopoietic Stem Cells

3.

Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients

4.

Beyond Symptoms: The Predictive Promise of Targeted Radionuclide Therapy in Palliative Oncology

5.

Precision Oncology: Cancer Screening, Genetic Counseling & Hereditary Cancer Syndromes Integration

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III

2.

Current Scenario of Cancer- Q&A Session to Close the Gap

3.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

4.

Should We Use DARA Up Front As First-Line Therapy in MM?

5.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

BPPV, history of gout associated with Ménière's disease

Latest News

Unraveling the Complexities of Concomitant IBD and Hepatobiliary Disease, With Natalia Nedelkopoulou, MD Natalia Nedelkopoulou, MD

Navigating Autoimmune Overlap in Celiac Disease, With Daniel Mallon, MD Daniel Mallon, MD

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD Bruce Sands, MD

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

Latest News

News All Time

Young Adults With IBD Face Greater Healthcare Access Challenges, Financial Burdens

Gastroenterology in 2025: Year in Review

Young Women With Ulcerative Colitis Face Higher Corticosteroid Exposure Risk

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD Thomas Wallach, MD

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

Recommended News For You

Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.

AI-based breast cancer risk technology receives FDA breakthrough device designation

O. A. J. Simpson passes away from cancer.

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.

Prostate cancer early detection system eliminates need for biopsy.

According to JAMA, even four minutes a day of exercise can lower the risk of cancer.

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

Recommended Articles For You

Understanding Extramammary Paget's Disease: Causes, Symptoms and Treatment Options

Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research

Autophagy: A Double-Edged Sword in Cancer Development, Immune Evasion, and Drug Resistance

Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.